Pheochromocytoma (benign or malignant)
The VA rates Pheochromocytoma (benign or malignant) under Diagnostic Code 7918 at a single 0% level. With a cap of 0%, most veterans pursue secondary conditions to increase their combined rating.
Rating schedule — DC 7918 at a glance
- Minimum rating
- 0%
- Maximum rating
- 0%
- Rating tiers
- 1
- CFR section
- § 4.119
- Body system
- Endocrine System
- Secondary conditions
- 0
Lowest schedular rating available
TDIU may raise effective compensation to 100%
0%
Part 4 rating schedule
None mapped
What are the VA rating criteria for Pheochromocytoma (benign or malignant)?
| Rating | Criteria |
|---|---|
| 0% | Note: Evaluate as malignant or benign neoplasm as appropriate. Note: Cross-reference — see referenced criteria for rating tiers |
“Note: Evaluate as malignant or benign neoplasm as appropriate.”
Common Questions About Pheochromocytoma (benign or malignant) VA Ratings
What is the VA rating range for Pheochromocytoma (benign or malignant)?
The VA rates Pheochromocytoma (benign or malignant) under Diagnostic Code 7918 at 0%. The minimum 0% rating requires: Note: Evaluate as malignant or benign neoplasm as appropriate.. The maximum 0% rating requires: Note: Evaluate as malignant or benign neoplasm as appropriate..
Which 38 CFR diagnostic code does the VA use for Pheochromocytoma (benign or malignant)?
The VA rates Pheochromocytoma (benign or malignant) under Diagnostic Code (DC) 7918, governed by 38 CFR 38 CFR § 4.119. The diagnostic code establishes the specific rating tiers and severity criteria the VA examiner applies.
Can Pheochromocytoma (benign or malignant) qualify for TDIU?
Pheochromocytoma (benign or malignant) maxes at 0%, well below the single-disability TDIU threshold. However, combined with other service-connected disabilities, TDIU may be achievable under 38 CFR § 4.16. Focus on establishing secondary conditions to increase the combined rating.
What evidence supports a higher rating for Pheochromocytoma (benign or malignant)?
The key evidence for Pheochromocytoma (benign or malignant) is documentation of how the condition affects daily functioning. Treatment records showing worsening symptoms, functional limitations documented by your provider, and buddy statements describing observable impact on daily life all strengthen the claim. A nexus letter from a qualified medical professional linking the current severity to service is essential for contested claims.
What happens at the C&P exam for Pheochromocytoma (benign or malignant)?
The C&P examiner uses a Endocrine System DBQ and evaluates your condition against the DC 7918 rating criteria. The examiner documents symptom frequency, severity, and functional impact. Bring all treatment records and describe your worst days, not your best — the VA rates on the full clinical picture across time, not a snapshot of one good day.
Get a Personalized Rating Analysis
VeteranHQ evaluates your symptoms against the exact 38 CFR criteria, identifies secondary conditions, and shows what evidence you need to support a higher rating.
Discover Your Benefits